Tags : Adalimumab Biosimilar


Innovent’s Sulinno (Adalimumab biosimilar) Receives China’s NMPA Approval for Pediatric

Shots: The approval is granted in pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults, who do not respond adequately to corticosteroids. These are fifth and sixth approved indications of Sulinno in China and it was first approved by NMPA on Sep 2, 2020 Sulinno is an adalimumab biosimilar which is […]Read More


Alvotech and DKSH Extend their Collaboration to Commercialize Six Biosimilars

Shot:   The companies expand their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets In Mar’2020, the companies collaborated for AVT02 (biosimilar, adalimumab). The collaboration targets Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh, and Pakistan The expansion deepens the partnership b/w the two companies […]Read More

Biosimilars Biotech Regulatory

Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”

Shots: Hulio’s EU Marketing Approval is followed after CHMP approval that demonstrated analytical, functional, clinical and immunogenicity data similar to AbbVie’s Humira In 2018, Kyowa and Mylan signed an agreement for exclusive commercialization right of Hulio in EU, and is expect to launch on or after 16 Oct, 2018 Adalimumab is an injectable, biologic medication […]Read More